Isoliquiritigenin limits inflammasome activation of macrophage via docking into Syk to alleviate murine non‐alcoholic fatty liver disease

Abstract Isoliquiritigenin (ISL) is a chalcone‐type flavonoid derived from the root of licorice with antioxidant, anti‐inflammatory, anti‐tumour and neuroprotective properties. ISL has been proven to downregulate the productions of IL‐1β, TNF‐α and IL‐6 by macrophages. However, detailed molecular mechanisms of this modulation remain elusive. Here, ISL suppressed Syk phosphorylation and CD80, CD86, IL‐1β, TNF‐α and IL‐6 expressions in lipopolysaccharide‐stimulated macrophages ex vivo. ApoC3‐transgenic (ApoC3 TG ) mice had more activated macrophages. ISL was also able to downregulate the inflammatory activities of macrophages from ApoC3 TG mice. Administration of ISL inhibited Syk activation and inflammatory activities of macrophages in ApoC3 TG mice in vivo. The treatment of ISL further alleviated MCD‐induced non‐alcoholic fatty liver disease (NAFLD) in wild‐type and ApoC3 TG mice, accompanied by less recruitment and activation of liver macrophages. Due to the inhibition of Syk phosphorylation, ISL‐treated macrophages displayed less production of cytoplasmic ROS, NLRP3, cleaved‐GSDMD and cleaved‐IL‐1β, suggesting less inflammasome activation. Finally, the molecular docking study demonstrated that ISL bound to Syk directly with the K d of 1.273 × 10 −8 M. When the Syk expression was knocked down by its shRNA, the inhibitory effects of ISL on activated macrophages disappeared, indicating that Syk was at least one of key docking‐molecules of ISL. Collectively, ISL could alleviate MCD‐induced NAFLD in mice involved with the inhibition of macrophage inflammatory activity by the blockade of Syk‐induced inflammasome activation.